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Abstract
Background: Evidence is accumulating for a role of vitamin D in maintaining normal glucose homeostasis. However, studies
that prospectively examined circulating concentrations of 25-hydroxyvitamin D (25-[OH] D) in relation to diabetes risk are
limited. Our objective is to determine the association between maternal plasma 25-[OH] D concentrations in early
pregnancy and the risk for gestational diabetes mellitus (GDM).
Methods: A nested case-control study was conducted among a prospective cohort of 953 pregnant women. Among them,
57 incident GDM cases were ascertained and 114 women who were not diagnosed with GDM were selected as controls.
Controls were frequency matched to cases for the estimated season of conception of the index pregnancy.
Results: Among women who developed GDM, maternal plasma 25-[OH] D concentrations at an average of 16 weeks of
gestation were significantly lower than controls (24.2 vs. 30.1 ng/ml, P,0.001). This difference remained significant
(3.62 ng/ml lower on average in GDM cases than controls (P value=0.018)) after the adjustment for maternal age, race,
family history of diabetes, and pre-pregnancy BMI. Approximately 33% of GDM cases, compared with 14% of controls
(P,0.001), had maternal plasma 25-[OH] D concentrations consistent with a pre-specified diagnosis of vitamin D deficiency
(,20 ng/ml). After adjustment for the aforementioned covariates including BMI, vitamin D deficiency was associated with a
2.66-fold (OR (95% CI): 2.66 (1.01–7.02)) increased GDM risk. Moreover, each 5 ng/ml decrease in 25-[OH] D concentrations
was related to a 1.29-fold increase in GDM risk (OR (95% CI): 1.29 (1.05–1.60)). Additional adjustment for season and physical
activity did not change findings substantially.
Conclusions: Findings from the present study suggest that maternal vitamin D deficiency in early pregnancy is significantly
associated with an elevated risk for GDM.
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Introduction
Vitamin D, a secosteroid that is synthesized in skin and
sequentially metabolized in liver and kidneys in humans, has been
well-known for its function in maintaining calcium and phospho-
rus homeostasis and promoting bone mineralization. However, the
ubiquitous distribution of intracellular vitamin D receptor across
diverse tissues [1] and the emerging epidemiological evidence
documenting increased risks of hypertension [2,3], cardiovascular
disease [4–7], and selected cancers [1,8] associated with vitamin D
deficiency underscore the pleiotropic actions of vitamin D.
Evidence is also accumulating for a role of vitamin D in
maintaining normal glucose homeostasis. For instance, in both
animal and human studies, vitamin D depletion was significantly
related to insulin resistance and impaired insulin secretion.
Notably, this condition is reversible upon repletion of vitamin D
[9–12]. Moreover, a significant and strong association between
vitamin D deficiency and ß-cell dysfunction has been reported in
healthy, non-diabetic, or diabetic populations [13–15]. Further-
more, circulating concentrations of 25-hydroxyvitamin D (25-
[OH] D), the primary circulating form of vitamin D, were
significantly and inversely related to the risk for type 2 diabetes[15]
and related phenotypes in epidemiological studies [9,16–19].
It has long been known that vitamin D deficiency is prevalent
among pregnant women [20–22]. For instance, recent data among
pregnant women in northern United States indicated that vitamin
D deficiency occurred in 29.2% of black women and 5% of white
women [23]. Data on the role of vitamin D in glucose homeostasis
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mellitus (GDM) are scant and findings are inconsistent. In a cross-
sectional study [24], serum concentrations of 25-[OH] D
measured at the time of GDM screening test (24–28 weeks of
gestation) were significantly lower in GDM women than in normal
glucose tolerance pregnant women (16.49 vs. 22.97, p=0.009).
Similarly, in another study [25], maternal serum 25-[OH] D
concentrations measured at the time of GDM screening test were
significantly and inversely associated with fasting glucose. In an
Indian population, no significant association between 25-[OH] D
concentrations and GDM risk was observed [26]. Findings from
these studies are interesting, inference is, however, hindered by
ambiguous temporal relationship between circulating concentra-
tions of 25-[OH] D and GDM risk due to their cross-sectional
design. In the present study, we evaluated the association between
maternal plasma vitamin D concentrations in early pregnancy and




This nested case-control study was based on an ongoing
prospective cohort study of pregnant women, the ‘‘Omega Study’’
[27]. In this cohort, participants were recruited from women
attending prenatal care at clinics affiliated with Swedish Medical
Center in Seattle and Tacoma General Hospital in Tacoma,
Washington. Women were ineligible if they initiated prenatal care
after 20 weeks gestation, were younger than 18 years of age, did not
speak and readEnglish,didnotplan to carry the pregnancyto term,
or did not plan to deliver at either of the two research hospitals.
Participantscompleteda questionnaire administeredin English by a
trained interviewer at or near enrollment. These questionnaires
were used to gather information on socio-demographic, anthropo-
morphic, and behavioral characteristics and reproductive and
medical histories. After delivery, maternal and infant medical
records were abstracted for information on the course and outcome
of pregnancy. The procedures used in the Omega Study were in
agreement with the protocols approved by the Institutional Review
Boards of Swedish Medical Center and Tacoma General Hospital.
All participants provided written informed consent.
The analytical population was selected from pregnant women
who enrolled in the Omega Study between September 2002 and
October 2004. During this period, a total of 953 pregnant women
provided blood samples and completed interviews. Among them,
we identified and sampled all 57 women who developed GDM
and we randomly sampled 114 women who were not diagnosed
with GDM as controls. Controls were frequency matched to cases
for the estimated season of conception of the index pregnancy (i.e.
spring, summer, autumn, winter).
Data collection
From structured questionnaire and medical records, we obtained
information of covariates including maternal age, educational
attainment, height, pre-pregnancy weight, reproductive and
medical histories, and medical histories of first-degree family
members. We also collected information on annual household
income and maternal smoking before and during pregnancy. Pre-
pregnancy body mass index (BMI) was calculated as pre-pregnancy
weight in kilograms divided by height in meters squared. Maternal
medical records were reviewed to collect detailed medical and
clinical information. In our study settings, according to the
recommendations from the American Diabetes Association (ADA)
[28], pregnant women were screened at 24–28 weeks gestation
using a 50 gram 1-hour oral glucose challenge test. Those patients
who failed this screening test (glucose$7.8 mmol/L) were then
followed-up within 1–2 weeks with a 100g, 3-h oral glucose
tolerance test (OGTT). We also abstracted laboratory results from
participants’ 50 gram 1-hour glucose challenge test and from the
diagnostic 100 gram 3-hour OGTT. Women were diagnosed with
GDM if two or more of the 100 gram OGTT glucose levels
exceeded the ADA criteria [28]: fasting .5.3 mmol/L; 1-hour
.10.0 mmol/L; 2-hour .8.6 mmol/L; 3-hour .7.8 mmol/L.
Participants provided a 20 ml non-fasting blood sample around
16 weeks of gestation and reported the hours since last eating at
the time of the blood draw. Immediately after blood samples were
collected, they were fractionated by using standard procedures and
stored at 280uC until analysis. Plasma 25-(OH) D concentrations
were measured using DiaSorin enzyme immunoassay reagents and
procedures (Metametrix, Norcross, GA). Intra-assay and inter-
assay coefficients of variation for this method are both #12%.
Statistical analysis
We estimated the correlation between plasma 25-[OH] D
concentrations and maternal pre-pregnancy BMI using Pearson’s
correlation coefficients (r). Because the distribution of plasma 25-
[OH] D concentrations was approximately normally distributed,
we examined differences in mean concentrations between cases
and controls using the Student’s t test. We categorized plasma 25-
[OH] D concentrations according to previously published criteria
for vitamin D sufficiency ($30 ng/ml), insufficiency (20–29 ng/
ml) and deficiency (,20 ng/ml) [1]. We used logistic regression
models to estimate odds ratios (OR) and 95% confidence interval
(95% CI). We evaluated the covariates in Table 1 as potential
confounders and included in the final model those that altered
unadjusted ORs by 10% or more, including maternal age, race/
ethnicity, family history of type 2 diabetes, and pre-pregnancy
BMI. Inclusion of physical activity in the model only slightly
changed the ORs (,3%), therefore, we didn’t include it in the final
model. All analyses were performed using Stata 9.0 (Stata, College
Station, TX). All reported confidence intervals were calculated at
the 95% level and all reported p-values are two-tailed.
Results
In general, women who developed gestational diabetes were
older, heavier, more likely to have a positive family history of type 2
DM, and less likely to be Non-Hispanic White as compared with
controls (Table 1). Moreover, the majority of study participants
reported consuming prenatal multivitamins (86% in cases and 92%
in controls, P for difference=0.21). As expected, maternal plasma
25-[OH] D concentrations were inversely associated with maternal
adiposity as estimated by pre-pregnancy BMI (r=20.28, p=0.04
in GDM cases; r=20.25, P=0.01 in controls).
Maternal plasma 25-[OH] D concentrations were 20% lower,
on average, among women who subsequently developed GDM, as
compared with those who were not diagnosed with GDM
(Figure 1). Notably, this difference in maternal plasma 25-
[OH] D concentrations remained statistically significant (3.62 ng/
ml lower on average in GDM cases than controls (P value=0.018))
after the adjustment for maternal age, race/ethnicity, family
history of diabetes, and pre-pregnancy BMI Similar findings were
observed when we restricted our analyses to women without a
history of GDM (mean6SD, GDM cases vs. controls: 24.968.2 vs.
29.769.4 ng/ml, P=0.003).
Approximately 33% of GDM cases, compared with 14% of
controls(P,0.001),had plasma25-[OH]D concentrations consistent
with a diagnosis of vitamin D deficiency (,20 ng/ml)) [1] (Table 2).
Vitamin D and GDM
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increased subsequent risk of GDM, as compared with vitamin D
sufficient women ($30 ng/ml) after adjustment for maternal age,
race/ethnicity, first-degree family history of type 2 diabetes (adjusted
OR=3.74, 95% CI, 1.47–9.50). In addition, we analyzed plasma 25-
[OH] D concentrations as continuous variables. From the multivar-
iate analysis, each 5 ng/ml decrease in plasma 25-[OH] D
concentrations was associated with a 1.36-fold (95% CI, (1.11–
1.69)) reduction in GDM risk. Further adjustment for maternal pre-
pregnancy BMI attenuated the association, though, it remained
statistically significant. When we restricted this analysis to Non-
Hispanic Whites, the majority of our study participants (40 GDM
cases and 96 controls), 25-[OH] D deficiency was associated with an
increased risk after the adjustment for BMI and other covariates
(OR=3.77, 95% CI 1.19–11.9). Among Non-Hispanic Whites, each
5 ng/mldecrease inplasma 25-[OH]D concentrationwasassociated
with a 1.29-fold increase in GDM risk (adjusted OR (95% CI), 1.29
(1.05–1.69)).
We further examined the independent and joint effect of
maternal plasma 25-[OH] D concentrations and overweight status
on the risk of GDM. The association of GDM with 25-[OH] D
concentrations was similar for overweight (BMI$25 kg/m
2) and
lean women (BMI ,25 kg/m
2) (P for interaction 0.93). The risk
for GDM was highest for overweight women who were classified
as being deficient for vitamin D (25-[OH] D,20 ng/ml in
pregnancy); they experienced an approximately 5-fold increased
risk as compared with lean women of higher plasma 25-[OH] D
levels (adjusted OR=4.93, 95% CI 1.63–14.9) (Table 3).
Discussion
In the present study, maternal plasma 25[OH] D concentra-
tions in early pregnancy were significantly and inversely associated
with GDM risk. This association remained statistically significant
even after controlling for established risk factors of GDM
including maternal age, family history of type 2 diabetes, race/
ethnicity, and pre-pregnancy BMI.
The major sources of vitamin D in the body are dietary vitamin
D intake and supplementation as well as endogenous production
of vitamin D in the skin exposed to sunlight. The biologically
active form of vitamin D is 1,25-[OH] D. However, 25-[OH] D is
regarded as the best indicator of vitamin D status in the body
Table 1. Characteristics of study participants according to gestational diabetes (GDM) case-control status.
Characteristics GDM Cases Controls P-value
(N=57) (N=114)
n( % ) n( % )
Maternal Age at interview (years) 34.364.8
1 33.163.9 0.09
,35 29 (50.9) 72 (63.2) 0.12
$35 28 (41.1) 42 (36.8)
Maternal Race/Ethnicity
White/Non-Hispanic 40 (70.2) 96 (84.2) 0.03
African American 2 (3.5) 6 (5.3)
Others 15 (26.3) 12 (10.5)
Nulliparous 27 (47.4) 62 (54.4) 0.39
Consumed Prenatal Vitamins 49 (86.0) 105 (92.1) 0.21
Consumed$2 Servings of Fish Weekly 27 (47.4) 65 (57.0) 0.23
Consumed$1 Glass of Milk Daily 22 (38.6) 42 (36.8) 0.82
Smoked During Pregnancy 3 (5.3) 7 (6.1) 0.82
Family History of Diabetes Mellitus 14 (24.6) 15 (13.2) 0.06
Physical Inactivity During Pregnancy 9 (15.8) 9 (7.9) 0.11
Pre-Pregnancy Body Mass Index (kg/m
2) 26.767.2
1 23.363.8 0.001
Pre-Pregnancy Body Mass Index (kg/m
2)
,25 29 (50.9) 84 (73.7) 0.003
$25 28 (49.1) 30 (26.3)
Gestational Age at Blood Collection (weeks) 16.362.1
1 16.162.2 0.59
Gestational Age at Glucose Screening Test (weeks) 26.962.6
1 26.462.5 0.25
Season of Estimated Time of Conception*
(March–May) Spring 21 (36.8) 42 (36.8) 1.00
(June–August) Summer 17 (29.8) 34 (29.8)
(September–November) Autumn 13 (22.8) 26 (22.8)
(December–February) Winter 6 (10.5) 12 (10.5)
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1,25-[OH] D and has a longer biological half-life and higher
concentrations in circulation than 1,25-[OH] D. Plasma 25-[OH]
D reflects vitamin D from both endogenous and exogenous
sources.
It has become increasingly clear that vitamin D has physiolog-
ical functions beyond bone health [6]; vitamin D receptors were
expressed in a large number of other tissues including those
involved in the regulation of glucose metabolism, such as muscle
and pancreatic b cells [1]. GDM was hypothesized to result from
pregnancy induced insulin resistance and impaired insulin
secretion to compensate for it [28,29]. Several mechanisms may
explain the observed association between vitamin D deficiency and
GDM risk. First, vitamin D may directly or indirectly modulate
pancreatic b-cell function and secretion by binding its circulating
active form, 1,25-[OH]D, to b-cell vitamin D receptor and
regulating the balance between the extracellular and intracellular
b-cell calcium pools [12,30]. Second, vitamin D can promote
insulin sensitivity by stimulating the expression of insulin receptors
and enhancing insulin responsiveness for glucose transport. It also
regulates extracellular calcium and thus ensures normal calcium
influx through cell membranes and an adequate intracellular
cytosolic calcium pool, which is essential for insulin-mediated
intracellular processes in insulin-responsive tissues [31]. Lastly, it is
possible that the observed inverse association of plasma 25-[OH]
D with GDM risk reflects the impact of other components of
major endogenous and exogenous sources of vitamin D on glucose
homeostasis through other pathways. For instance, endogenous
production of vitamin D in the skin due to sun exposure is a major
source of plasma 25-[OH] D. Sun exposure could be positively
correlated with outdoor physical activity, a protective factor for
insulin resistance and GDM [32–34]. In the present study, the
inverse association between plasma 25-[OH] D concentrations
and GDM risk persisted after controlling for physical activity.
Data relating vitamin D to the risk for GDM are sparse. Our
findings are in line with those from one cross-sectional study,
where serum concentrations of 25[OH] D levels during 24–28
weeks of gestation were significantly lower in GDM women than
in normal groups. [24] In another study [35], maternal serum 25-
[OH] D concentrations measured at the time of GDM screening
test were significantly and inversely associated with fasting glucose,
although the association with GDM risk was not statistically
significant. In a study among an Indian population, no significant
association between 25-[OH] D concentrations (30 weeks of
Table 2. Odds ratios (OR) and 95% confidence intervals (CI) for gestational diabetes (GDM) according to maternal plasma 25-
hydroxyvitamin D (25(OH)D) concentrations in pregnancy.
25(OH)D (ng/ml) GDM Cases Controls Unadjusted Adjusted
* Adjusted
**
(N=57) (N=114) OR (95% CI) OR (95% CI) OR (95% CI)
All Subjects
25(OH)D (categorical variable)
Sufficient ($30) 14 51 1.00 (referent) 1.00 (referent) 1.00 (referent)
Insufficient (20–29) 24 47 1.86 (0.86–4.01) 1.86 (0.84–4.09) 1.56 (0.69–3.52)
Deficient (,20) 19 16 4.33 (1.78–10.5) 3.74 (1.47–9.50) 2.66 (1.01–7.02)
P for trend 0.001 0.006 0.05
25(OH)D(continuous variable)
Per 5 ng/ml reduction 1.44 (1.16–1.69) 1.36 (1.11–1.69) 1.29 (1.05–1.60)
Non-Hispanic Whites
25(OH)D (categorical variable)
Sufficient ($30) 11 45 1.00 (referent) 1.00 (referent) 1.00 (referent)
Insufficient (20–29) 16 42 1.56 (0.65–3.74) 1.58 (0.65–3.87) 1.21 (0.47–3.09)
Deficient (,20) 13 9 5.91 (2.02–17.3) 5.40 (1.78–16.4) 3.77 (1.19–11.9)
P for trend 0.002 0.005 0.04
25(OH)D (continuous variable)
Per 5 ng/ml reduction 1.44 (1.16–1.79) 1.44 (1.11–1.79) 1.29 (1.05–1.69)
Vitamin D deficiency was defined using cut-points given by Holick, MF ([reference 1]).
*Adjusted for maternal age, race/ethnicity and family history of diabetes.
**Adjusted for maternal age, race/ethnicity and family history of diabetes as well as pre-pregnancy body mass index.
doi:10.1371/journal.pone.0003753.t002
Figure 1. Maternal plasma 25-Hydroxyvitamin D concentra-
tions in pregnancy among 57 GDM cases and 114 controls.
Vertical bars indicate means6SD (standard deviation).
doi:10.1371/journal.pone.0003753.g001
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studies are interesting, inference is, however, hindered by
ambiguous temporal relationship between circulating concentra-
tions of 25-[OH] D and GDM because 25-[OH] D concentrations
were measured in late pregnancy when GDM likely developed.
Our findings are also generally consistent with a relatively large
body of literature documenting a significant and inverse
association of circulating vitamin D concentrations with measure-
ments of glycemia or presence of type 2 DM among non-pregnant
women, although the majority of these findings are based on cross-
sectional/retrospective data. For instance, serum 25-[OH]D
concentrations (after multivariate adjustment) were inversely
associated with the prevalence of diabetes in a dose-dependent
pattern in both non-Hispanic Whites and Mexican-Americans in a
large cross-sectional study [18]. Moreover, in a meta-analysis of
cross-sectional studies [36], the summary OR for type 2 DM was
0.54 (95% CI, 0.23–1.27) for the highest vs. the lowest 25-[OH]D
concentrations (25–38 vs. 10–23 ng/ml, respectively). When the
data on Non-Hispanic Blacks were excluded, 25-[OH]D concen-
trations were significantly and inversely associated with prevalent
type 2 DM [OR 0.36 (95% CI, 0.16–0.80)]. In the present study,
when we restricted this analysis to Non-Hispanic Whites, the
majority of our study participants, 25-[OH] D deficiency was
associated with 3.77-fold increased risk after the adjustment for
covariates. We do not have sufficient statistical power to examine
the association in other race/ethnicity groups. We are aware of
only one prospective study for type 2 DM thus far; an inverse
association of serum 25-[OH]D with the incidence of type 2 DM
was observed in a Finnish study [37]. Similarly, an inverse
association of baseline serum 25-[OH]D concentration with future
glucose levels and insulin resistance was observed in a recent
population-based study of non-diabetic men and women aged 40–
69 years [38].
Ourstudyhasseveralstrengths.First,determinationof25-[OH] D
concentrations using plasma collected in early pregnancy served to
define the temporal relationship between maternal vitamin D
deficiency and subsequent risk of GDM because, in general, pregnant
women develop gestational diabetes during the late 2
nd or 3
rd
trimester. We, however, cannot completely exclude the plausibility
that a limited number of women may have had undiagnosed pre-
pregnancy glucose intolerance when blood specimens were collected.
Second, the high follow-up rate (.95%) of women enrolled in our
study minimized possible selection bias. However, several limitations
also merit discussion and consideration. First, a single measurement
of plasma 25-[OH] D concentrations is not likely to provide a time-
integrated measure of maternal vitamin D status during the entire
study pregnancy. Longitudinal studies with serial measurements of
maternal plasma 25-[OH] D concentrations, indices of insulin
sensitivity and secretion are needed to elucidate the mechanisms and
patho-physiological consequences of maternal vitamin D deficiency
during pregnancy. Second, our study is relatively small and thus,
large prospective studies are needed to confirm our results. A further
limitation is the under representation of minority women in our study
populations. However, due to the predisposition of Asian, Black, and
Hispanic women for insulin resistance and vitamin D deficiency, it is
possible that adequate vitamin D status may be even more important
in these populations.
In conclusion, our study provides data indicating that maternal
vitamin D deficiency in early pregnancy (i.e. plasma 25-[OH] D
,20 ng/ml) is significantly associated with elevated risk for GDM
even after adjustment for conventional risk factors for diabetes.
Such evidence is valuable in view of the limited prospective data
on the relation of circulating vitamin D status to impaired glucose
tolerance in either pregnant or non-pregnant individuals. Vitamin
D deficiency is common among pregnant women and has been
associated with elevated risk for other pregnancy complications
such as preeclampsia and a number of serious short- and long-
term health problems in offspring [20,39]. Circulating vitamin D
can be modified by food consumption (e.g. fatty fish), supplement
use, and outdoor sun exposure. Intervention studies [14,40–44]
assessing the effect of vitamin D and calcium supplements on
glucose metabolism among non-pregnant individuals have yielded
mixed results, which is at least partly due to variations in the dose
of supplementation and the duration of follow up. Optimizing the
effective dose of vitamin D supplement continues to be a
challenge. If confirmed, our data raise the possibility that treating
vitamin D deficiency in pregnancy, via supplementation or lifestyle
measures, can contribute to the prevention of GDM.
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Table 3. Odds ratios (OR) and 95% confidence intervals (CI) for gestational diabetes (GDM) according to both maternal plasma 25-
Hydroxyvitamin D deficient status and pre-pregnancy overweight status.
Vitamin D deficiency* Overweight** GDM Cases Controls Unadjusted OR (95% CI) Adjusted
1 OR (95% CI)
(N=57) (N=114)
No No 22 75 1.00 (referent) 1.00 (referent)
Yes No 7 9 2.65 (0.89–7.93) 2.36 (0.75–7.43)
No Yes 16 23 2.37 (1.07–5.25) 2.24 (0.99–5.08)
Yes Yes 12 7 5.84 (2.05–16.6) 4.93 (1.63–14.9)
P value for interaction term 0.93 0.93
*Vitamin D deficiency is defined as maternal plasma 25-Hydroxyvitamin D concentrations ,20 ng/ml (Holick MF, [reference 1]).
**Overweight is defined as pre-pregnancy body mass index (BMI) $25 kg/m
2.
1Adjusted for maternal age, race/ethnicity, and family history of diabetes.
doi:10.1371/journal.pone.0003753.t003
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